Abbott (NYSE: ABT) will announce its fourth-quarter 2021 financial results on Wednesday, Jan. 26, 2022, before the market opens.
AT&T is teaming up with Smart Meter to improve health outcomes for patients with chronic conditions like diabetes and high blood pressure.
#product & service
#rpm
My Diabetes My Way (MDMW) is Scotland’s interactive website and mobile app for people with diabetes and their caregivers. This study aims to assess the cost-utility of MDMW compared with routine diabetes care in people with type 2 diabetes who do not use insulin.
#mobile app
It is not clear how the short-term continuous glucose monitoring (CGM) sampling time could influence the bias in estimating long-term glycemic control. This study sought to investigate the relation between sampling time and bias in the estimates.
#cgm
The bacterial derived flavin adenine dinucleotide (FAD)-dependent glucose dehydrogenase (FADGDH) is the most promising enzyme for the third-generation principle-based enzyme sensor for continuous glucose monitoring (CGM).
#cgm
One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, today announced it has been honored in the 2022 Best Places to Work Awards by Built In.
Welldoc®, a digital health leader revolutionizing chronic care, announced that the company’s 25th patent was approved by the U.S. Patent and Trademark Office on December 8, 2021.
Good Parents Inc., creators of the Kiddo remote patient monitoring (RPM) and continuous care platform for pediatric patients, announced it has closed a $16 million Series A growth investment led by Clearlake Capital-backed Vive Collective. Kiddo serves at-risk children who require proactive and continuous care due to such chronic conditions as asthma, heart disease, autism, and diabetes.
The new clients include a large Northeast regional employer in the finance industry set to deploy Dario's full suite of solutions, and a Northeast regional employer in the food industry contracted to deploy Dario's digital therapeutic solution for diabetes.
The company announced it's developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body - such as glucose, ketones, and lactate - to help people better understand their general health and take action.